Container Closure Integrity Testing

Overview

This course focuses on theoretical and practical fundamentals of various CCI testing technologies and provides a systematic approach to apply these testing methods for CCI verification throughout drug product lifecycle. The course will enable the participants to implement CCI testing strategies to ensure adequate drug product protection and be compliant with relevant regulatory and compendia requirements. In this course, participants gain critical problem solving skills through:

- interactive discussions with a panel of cross-functional technical experts consisting of CCI testing laboratory
 experts, testing instrument suppliers/manufacturers, and pharmaceutical packaging development engineers
- · hands-on testing training on the newest innovations and state-of-the-art instruments
- real-world case studies

Who Should Attend

- · Parenteral drug packaging engineers and formulation scientists
- · Laboratory scientific staff and managers
- · Parenteral manufacturing staff
- · Sterility Quality Assurance
- · Regulatory affair scientists
- · Pharmaceutical packaging component manufacturing staff

Presentation of Technology, Instruments Demo and Hands-on Training kindly supported by several suppliers of Container Closure Integrity testing systems and services

Learning Objectives

This course utilizes lectures, case studies, and interactive hands-on training on testing instruments to provide insight into the latest developments of Container Closure Integrity (CCI) Testing, with focus on achieving the following key objectives:

- Understanding up-to-date regulatory and pharmacopeia requirements on CCI.
- Defining CCI requirements for various container and drug product types using a risk-based approach.
- Explaining working principles of various CCI testing techniques and their practical applications, with focus on deterministic methods such as tracer gas detection (e.g. helium leak detection), electrical conductivity and capacitance (HVLD), vacuum decay leak detection, laser-based gas headspace analysis, mass extraction leak test.

- Selecting and applying appropriate testing methods for both laboratory and in-process testing to formulate comprehensive package integrity verification profiles.
- Defining CCI testing method development and validation approach and best practices.
- Avoiding common issues and pitfalls in CCI testing applications.



Lei Li, PhD, Associate Engineer Advisor Delivery and Device R&D, Eli Lilly

Lei Li currently serves as an engineer advisor at Delivery and Device R&D, Eli Lilly and Company. Lei has 9 years of experience in pharmaceutical and medical device industry, with focus on developing API and drug product packaging in support of clinical development and product commercialization, and establishing cold-chain distribution for biologic products. His current responsibilities include developing package integrity verification profiles for Lilly's diverse pipeline portfolio, developing and validating CCI testing methods, and supporting commercial control strategy development for CCI verification throughout drug product and device life cycle. He is a frequent speaker at PDA conferences and author of peer-reviewed articles and book chapters on CCI test methods. Lei Li received his Ph. D. in Analytical Chemistry from West Virginia University; prior to joining Eli Lilly, he worked at GE Plastics as an analytical and material scientist.

31 Juli 2019

Thurs	sday, 24 October 2019 9:00 – 17:30	Friday	y, 25 October 2019 8:30 – 16:3
9:00	Welcome and Introduction	8:30	Application Case Studies - Part 2 · Vacuum and pressure decay
9:15	Regulatory Requirements: CCI introduction, regulatory requirements, and industry trends		Mass extraction
		9:10	Hands-on Training
10:00	 Introduction CCI assurance throughout product lifecycle Testing requirement definition – risk based approach CCI profile & testing strategy development 	10:10	Coffee Break
		10:40	Application Case Studies - Part 3Headspace analysisHVLD
10:30	Coffee Break	11:20	Hands-on Training
11:00	CCI defects and commonly used positive con-	12:00	Lunch Break
		13:00	Development and Validation of Integrity Test Methods
			 Method development best practices Method validation strategy
11:40	Methodologies for Sizing CCI Defects Using Gas Flow Dynamics		Pitfalls and solutionsA Case study
12:00	Lunch Break	14:10	Approaches to CCI Testing Method Selection
13:00	CCI Test Methods: Overview Deterministic vs probabilistic definitions Physicochemical methods vs microbiological methods: differences and correlations Microbial and dva ingrees testing basics.		Introduce group exercise: Product life cycle testing and method selection
		14:30	Coffee Break
14:00	 Microbial and dye ingress testing basics CCI Testing Technologies Vacuum and pressure decay Mass Extraction Headspace analysis HVLD Tracer gas (helium leak detection) Seal quality testing (residual seal force) 	15:00	Group Exercise - Breakout
		16:00	Group Exercise - Presentations & Discussion
		16:30	End of Course

15:00 Coffee Break

15:30 Current Topics: Industry Best-Practices and Novel Technologies

 AMI optical emission spectroscopy for CCI testing & demo

16:00 Application Case Studies - Part 1

- Tracer gas (helium leak detection)
- API container testing using helium leak detection & video

17:30 End of Day 1



Allison L. Dill, PhD, Senior Research Scientist, Eli Lilly and Company

Allison Dill, is a Senior Research Scientist in Delivery and Device Connected Solutions at Eli Lilly and Company, Indianapolis, IN. She received a BS in Chemistry and Biology from Indiana University, and worked for 4 years as an analytical chemist in Product Research and Development before attending graduate school. She received her Ph.D. in Analytical Chemistry from Purdue University, studying imaging mass spectrometry for disease state characterization. While at Lilly, she has been responsible for the analytical control strategy of many solid oral and parenteral dosage forms and has contributed to several regulatory submissions. Her recent contributions have focused on enabling the delivery of the early phase portfolio within a complex global network with responsibility for the analytical control strategy of both the active pharmaceutical ingredient and the drug product. She is now focusing on the CCI strategy for multiple molecules with a concentration in on-line high voltage leak detection for 100% inspection.